NCT01158235View on ClinicalTrials.gov

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Nasal Carriers MRSA
Interventions
DRUG

LTX-109

1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.

Trial Locations (1)

205 02

Skåne University Hospital, Malmo

Sponsors

Lead Sponsor

Lytix Biopharma AS
All Listed Sponsors
lead

Lytix Biopharma AS

INDUSTRY

NCT01158235 - A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA) | Biotech Hunter | Biotech Hunter